BiotechTube

Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type II;Pompe's Disease

Conditions

Glycogen Storage Disease Type II;Pompe's Disease

Trial Timeline

Nov 2, 2016 → May 31, 2023

NCT ID
NCT02782741

About Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)

Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) is a phase 3 stage product being developed by Sanofi for Glycogen Storage Disease Type II;Pompe's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02782741. Target conditions include Glycogen Storage Disease Type II;Pompe's Disease.

What happened to similar drugs?

3 of 6 similar drugs in Glycogen Storage Disease Type II;Pompe's Disease were approved

Approved (3) Terminated (0) Active (3)
✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
✅Avalglucosidase alfa (GZ402666)SanofiApproved
✅Avalglucosidase alfaSanofiApproved
🔄avalglucosidase alfaSanofiPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03019406Phase 2Active
NCT02782741Phase 3Completed

Competing Products

20 competing products in Glycogen Storage Disease Type II;Pompe's Disease

See all competitors
ProductCompanyStageHype Score
mRNA-3745ModernaPhase 2
0
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
43
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
Alglucosidase alfa GZ419829SanofiPre-clinical
30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
33
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
34
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18